{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000062","form_type":"8-K/A","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.219490+00:00","generated_at":"2026-05-17T03:31:02.223199+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Supernus closes Sage acquisition for $8.50/share + CVRs; pro forma shows $118M H1 loss","bullets":["Acquisition closed July 31, 2025; Supernus paid $8.50 per share cash plus CVRs up to $3.50 per share.","Pro forma net loss of $118.2M for six months ended June 30, 2025; $415.9M loss for FY 2024.","Contingent consideration liability of $35.7M recorded for CVRs tied to ZURZUVAE sales milestones.","Sage's marketed drug ZURZUVAE (postpartum depression) added to Supernus portfolio; collaboration with Biogen.","Supernus funded acquisition with cash and marketable securities; equity awards settled in cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000062","json":"https://secwatch.observer/filing/0001356576-25-000062.json","markdown":"https://secwatch.observer/filing/0001356576-25-000062.md","text":"https://secwatch.observer/filing/0001356576-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000062/0001356576-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000062/supn-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:31:02.223199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}